Using small molecules to improve proteasome function in neurodegenerative diseases
Overcoming proteasome impairment with small molecules
This study is exploring a new way to help people with Alzheimer's and similar diseases by using small molecules to boost the body's natural protein cleanup system, which could help stop harmful proteins from building up and worsening the condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-11018054 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating neurodegenerative diseases like Alzheimer's by enhancing the activity of the 20S proteasome using small molecules. The goal is to prevent the accumulation of harmful proteins that contribute to disease progression. By focusing on the degradation of intrinsically disordered proteins, the research aims to restore proteasome function that is impaired by these proteins. This innovative strategy could lead to new therapeutic options for patients suffering from these conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with neurodegenerative diseases, particularly those in the early stages of Alzheimer's disease or related dementias.
Not a fit: Patients with advanced neurodegenerative diseases or those who do not have a diagnosis of Alzheimer's disease or related dementias may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that slows or prevents the progression of neurodegenerative diseases.
How similar studies have performed: While this approach is innovative, similar strategies targeting proteasome function have shown promise in preliminary studies, indicating potential for success.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Tepe, Jetze J. — University of Virginia
- Study coordinator: Tepe, Jetze J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.